Brokerages Set Homology Medicines Inc (FIXX) PT at $29.50

Homology Medicines Inc (NASDAQ:FIXX) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $29.50.

Several equities analysts have recently weighed in on FIXX shares. Zacks Investment Research cut Homology Medicines from a “hold” rating to a “sell” rating in a report on Friday, December 28th. ValuEngine cut Homology Medicines from a “buy” rating to a “hold” rating in a report on Friday, December 7th. Finally, Canaccord Genuity started coverage on Homology Medicines in a report on Monday, January 7th. They set a “buy” rating and a $37.00 price objective on the stock.

FIXX traded up $0.46 during midday trading on Monday, reaching $21.89. 63,500 shares of the company were exchanged, compared to its average volume of 117,143. Homology Medicines has a one year low of $15.07 and a one year high of $26.50.

Homology Medicines (NASDAQ:FIXX) last issued its earnings results on Tuesday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.03). The business had revenue of $0.95 million during the quarter. As a group, equities analysts predict that Homology Medicines will post -1.49 earnings per share for the current year.

In other Homology Medicines news, major shareholder Ventures Iv L.P. 5Am sold 29,682 shares of the business’s stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $20.04, for a total value of $594,827.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kush Parmar sold 15,575 shares of the business’s stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $26.01, for a total value of $405,105.75. The disclosure for this sale can be found here. Insiders have sold a total of 571,157 shares of company stock worth $11,623,113 in the last quarter.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in Homology Medicines by 29.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,251,444 shares of the company’s stock valued at $51,468,000 after acquiring an additional 516,156 shares in the last quarter. BlackRock Inc. lifted its stake in Homology Medicines by 134.3% in the 4th quarter. BlackRock Inc. now owns 1,460,449 shares of the company’s stock valued at $32,656,000 after acquiring an additional 837,099 shares in the last quarter. Vanguard Group Inc. lifted its stake in Homology Medicines by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 473,945 shares of the company’s stock valued at $10,834,000 after acquiring an additional 3,504 shares in the last quarter. Vanguard Group Inc lifted its stake in Homology Medicines by 0.7% in the 3rd quarter. Vanguard Group Inc now owns 473,945 shares of the company’s stock valued at $10,834,000 after acquiring an additional 3,504 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in Homology Medicines by 2.6% in the 3rd quarter. Franklin Resources Inc. now owns 393,765 shares of the company’s stock valued at $9,001,000 after acquiring an additional 10,045 shares in the last quarter. Hedge funds and other institutional investors own 53.17% of the company’s stock.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

See Also: Diversification

Analyst Recommendations for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply